4.6 Review

Cancer and liver cirrhosis: implications on prognosis and management

Journal

ESMO OPEN
Volume 1, Issue 2, Pages -

Publisher

ELSEVIER
DOI: 10.1136/esmoopen-2016-000042

Keywords

-

Categories

Funding

  1. Austrian Science Fund [J 3747-B28]
  2. National Institutes of Health [P01 CA080124, R01 DK103879]
  3. Austrian Science Fund (FWF) [J 3747] Funding Source: researchfish
  4. Austrian Science Fund (FWF) [J3747] Funding Source: Austrian Science Fund (FWF)

Ask authors/readers for more resources

Liver cirrhosis, the end-stage of every chronic liver disease, is not only the major risk factor for the development of hepatocellular carcinoma but also a limiting factor for anticancer therapy of liver and non-hepatic malignancies. Liver cirrhosis may limit surgical and interventional approaches to cancer treatment, influence pharmacokinetics of anticancer drugs, increase side effects of chemotherapy, render patients susceptible for hepatotoxicity, and ultimately result in a competitive risk for morbidity and mortality. In this review, we provide a concise overview about the impact of liver cirrhosis on the management and prognosis of patients with primary liver cancer or non-hepatic malignancies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available